Recurrent Malignant Glioma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Recurrent Malignant Glioma – Drugs In Development, 2024 report and make more profitable business decisions.
Recurrent malignant glioma is defined as the recurrence of a glioma tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord, and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy.
The Recurrent Malignant Glioma drugs in development market research report provide comprehensive information on the therapeutics under development for Recurrent Malignant Glioma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Recurrent Malignant Glioma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 12 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Recurrent Malignant Glioma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Recurrent Malignant Glioma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Recurrent Malignant Glioma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Candel Therapeutics IncCity of Hope
FUDA Cancer Hospital
Hebei Senlang Biotechnology Co Ltd
Keio University
Moleculin Biotech Inc
Norwegian University of Science and Technology
Oblato Inc
PharmAbcine Inc
Rockefeller University
Smerud Medical Research International AS
Sumitomo Pharma Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Recurrent Malignant Glioma reports